cbdMD, Inc.
YCBD NYSE· Perfumes, Cosmetics & Other Toilet Preparations
Last close · Oct 26, 2026
$0.36
KIRA · Stoqly’s AI analyst, in plain words
- cbdMD, Inc. had $19.2M of revenue in fiscal 2025, down 1.5% on the year before. Over five years, revenue changed −14.5% a year on average.
- Its operating margin was −11.3%, up 5.7 pts: of every 100 in sales, about −11 is left after running the business.
- cbdMD, Inc. lost $2.0M in fiscal 2025.
- Free cash flow was −$1.6M in fiscal 2025, −8.5% of revenue.
Market cap
$1.5M
P/E
—
Revenue
$19.2M
Net income
−$2.0M
Free cash flow
−$1.6M
Operating margin
−11.3%
cbdMD, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−1.5%
No. Sales fell 1.5% last year.
Does it make a profit?
−10.6%
No. It lost money last year.
Does profit turn into cash?
−8.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What cbdMD, Inc. does
No business description yet.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 10-K · Dec 19, 2025
- Legal name
- cbdMD, Inc.
- CIK
- 0001644903
cbdMD, Inc. · YCBD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $44.5M | $35.4M | $24.2M | $19.5M | $19.2M |
| Revenue growth | 6.2% | −20.4% | −31.8% | −19.3% | −1.5% |
| Net interest income | −$0.0M | $0.0M | $0.1M | −$0.0M | $0.0M |
| Gross margin | 67.4% | 63.1% | 62.0% | 61.6% | 62.4% |
| Operating margin | −44.1% | −221.1% | −93.1% | −17.0% | −11.3% |
| Net income | −$23.4M | −$70.1M | −$22.9M | −$3.7M | −$2.0M |
| Net margin | −52.6% | −198.0% | −95.0% | −19.0% | −10.6% |
| Diluted EPS | −$0.47 | −$55.80 | −$13.32 | −$14.29 | −$1.09 |
| Cash | |||||
| Cash from operations | −$14.1M | −$15.0M | −$4.3M | −$0.4M | −$1.5M |
| Capital expenditure | $0.3M | $0.7M | $0.3M | $0.2M | $0.2M |
| Free cash flow | −$14.4M | −$15.7M | −$4.6M | −$0.5M | −$1.6M |
| FCF margin | −32.5% | −44.2% | −19.0% | −2.8% | −8.5% |
| Dividends paid | $2.6M | — | — | — | — |
| Share count change | 21.6% | −97.6% | 52.3% | −73.3% | 646.2% |
| Debt and strength | |||||
| Cash and short-term investments | $26.4M | $6.7M | $1.8M | $2.5M | $2.3M |
| Debt incl. finance leases | $0.1M | $0.1M | $0.0M | — | — |
| Shareholders' equity | $103M | $31.4M | $9.0M | $2.0M | $7.2M |
| Current ratio | 5.3x | 3.0x | 1.7x | 0.7x | 2.1x |
| Returns and quality | |||||
| Return on capital | −20.2% | −249.0% | −245.6% | — | — |
| Return on equity | −25.7% | −104.2% | −113.4% | −67.3% | −44.4% |
| Return on tangible equity | −110.6% | −545.2% | −463.5% | — | −85.8% |
| Piotroski F-score | 4 | 3 | 4 | 4 | 5 |
| Altman Z'' | 3.6 | −19.4 | −41.7 | −59.3 | −53.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.3M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
cbdMD, Inc. · YCBD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.36 a share, the company is worth $1.5M.
Source: SEC EDGAR XBRL filings (CIK 0001644903). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.